Bitcoin ETFs see record-high trading volumes as retail investors jump on crypto rally
https://www.cnbc.com/2024/02/28/bitcoin-etfs-see-record-high-trading-volumes-as-retail-investors-jump-on-crypto-rally.html
Feb 28, 2024 - The iShares Bitcoin Trust (IBIT) has already seen a record number of shares traded on Wednesday.
0
Wall Street Analysts See Bitfarms Ltd. (BITF) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2233166/wall-street-analysts-see-bitfarms-ltd-bitf-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2233166
Feb 28, 2024 - Based on the average brokerage recommendation (ABR), Bitfarms Ltd. (BITF) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
Cracker Barrel CEO Julie Felss Masino sees a long road ahead as Q2 traffic dips 4%
https://www.nrn.com/news/cracker-barrel-ceo-julie-felss-masino-sees-long-road-ahead-q2-traffic-dips-4
Feb 27, 2024 - The Tennessee-based casual-dining brand will focus on its new loyalty program, as well as strategic pricing and labor reductions, to improve the bottom line
0
Sealed Air (SEE) Q4 Earnings & Revenues Surpass Estimates
https://www.zacks.com/stock/news/2232562/sealed-air-see-q4-earnings-revenues-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2232562
Feb 27, 2024 - Sealed Air (SEE) witnesses year-over-year declines in its Q4 top and bottom lines due to lower volumes.
0
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231768/wall-street-analysts-see-a-56-18-upside-in-morphic-holding-inc-morf-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231768
Feb 26, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2231767/wall-street-analysts-see-a-131-6-upside-in-relay-therapeutics-inc-rlay-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2231767
Feb 26, 2024 - The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2230991/wall-street-analysts-see-a-70-57-upside-in-replimune-group-inc-repl-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230991
Feb 23, 2024 - The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2230992/wall-street-analysts-see-a-30-21-upside-in-arvinas-inc-arvn-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230992
Feb 23, 2024 - The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2230995/wall-street-analysts-see-an-185-54-upside-in-intellia-therapeutics-inc-ntla-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230995
Feb 23, 2024 - The consensus price target hints at an 185.5% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
0
Wall Street Analysts See Snowflake Inc. (SNOW) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2230882/wall-street-analysts-see-snowflake-inc-snow-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2230882
Feb 23, 2024 - The average brokerage recommendation (ABR) for Snowflake Inc. (SNOW) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0